中国医药导刊
中國醫藥導刊
중국의약도간
Chinese Journal of Medical Guide
2015年
10期
1028-1029,1032
,共3页
卡培他滨维持化疗%晚期胃癌%术后复发转移胃癌%耐受性%生存期
卡培他濱維持化療%晚期胃癌%術後複髮轉移胃癌%耐受性%生存期
잡배타빈유지화료%만기위암%술후복발전이위암%내수성%생존기
Capecitabine maintenance chemotherapy%Advanced gastric cancer%Recurrence and metastasis of gastric cancer%Tolerance%Survival
目的:探讨卡培他滨维持化学治疗(化疗)治疗晚期胃癌和术后复发转移胃癌的效果。方法:运用随机抽样的方法选取我院2013年1月~2014年9月收治的80例晚期胃癌和术后复发转移胃癌患者,依据治疗方法将这些患者分为研究组(n=40)和对照组(n=40)。给予对照组患者常规治疗,给予研究组患者常规治疗基础上的卡培他滨维持化疗治疗。结果:研究组患者治疗的总有效率60.0%(24/40)、85.0%(34/40)均显著高于对照组40.0%(16/40)、60.0%(24/40)(P<0.05),中位生存期显著长于对照组(P<0.05),1年、2年生存率均显著高于对照组(P<0.05)。结论:卡培他滨维持化疗治疗晚期胃癌和术后复发转移胃癌能够有效提高患者耐受性、延长生存期。
目的:探討卡培他濱維持化學治療(化療)治療晚期胃癌和術後複髮轉移胃癌的效果。方法:運用隨機抽樣的方法選取我院2013年1月~2014年9月收治的80例晚期胃癌和術後複髮轉移胃癌患者,依據治療方法將這些患者分為研究組(n=40)和對照組(n=40)。給予對照組患者常規治療,給予研究組患者常規治療基礎上的卡培他濱維持化療治療。結果:研究組患者治療的總有效率60.0%(24/40)、85.0%(34/40)均顯著高于對照組40.0%(16/40)、60.0%(24/40)(P<0.05),中位生存期顯著長于對照組(P<0.05),1年、2年生存率均顯著高于對照組(P<0.05)。結論:卡培他濱維持化療治療晚期胃癌和術後複髮轉移胃癌能夠有效提高患者耐受性、延長生存期。
목적:탐토잡배타빈유지화학치료(화료)치료만기위암화술후복발전이위암적효과。방법:운용수궤추양적방법선취아원2013년1월~2014년9월수치적80례만기위암화술후복발전이위암환자,의거치료방법장저사환자분위연구조(n=40)화대조조(n=40)。급여대조조환자상규치료,급여연구조환자상규치료기출상적잡배타빈유지화료치료。결과:연구조환자치료적총유효솔60.0%(24/40)、85.0%(34/40)균현저고우대조조40.0%(16/40)、60.0%(24/40)(P<0.05),중위생존기현저장우대조조(P<0.05),1년、2년생존솔균현저고우대조조(P<0.05)。결론:잡배타빈유지화료치료만기위암화술후복발전이위암능구유효제고환자내수성、연장생존기。
Objective: To investigate the effects of capecitabine maintenance chemotherapy in the treatment of advanced gastric cancer and recurrence and metastasis of gastric cancer.Methods:80 cases of advanced gastric cancer recurrence and metastasis of gastric cancer patients who were treated in our hospital from January 2013 to September 2014 were selected by random sampling method,they were divided into study group (n=40) and control group (n=40) according to the treatment methods.The control group were given conventional treatment,while the study group were given capecitabine maintenance chemotherapy on the basis of conventional treatment. Results:The total effective rate of the study group 60.0% (24/40), 85.0% (34/40) was significantly higher than the control group 40.0%(16/40), 60.0% (24/40) (P<0.05),the median survival time was significantly longer(P<0.05),the 1-year,2-year survival rate were significantly higher than the control group(P<0.05).Conclusion:Capecitabine maintenance chemotherapy can improve tolerance and prolong survival in the treatment of advanced gastric cancer and recurrence and metastasis of gastric cancer.